Eventide Asset Management, LLC 89bio, Inc. Transaction History

Eventide Asset Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$10.48 - $16.94 $6.73 Million - $10.9 Million	642,073 New	642,073 $9.78 Million
Q1 2022 May 16, 2022	SELL	$3.45 - $14.99 $2.47 Million - $10.7 Million	-716,670 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$11.15 - $19.66 $4.69 Million - $8.27 Million	-420,422 Reduced 36.97%	716,670 $9.37 Million
Q2 2021 Aug 16, 2021	SELL	$17.42 - $28.0 $2.29 Million - $3.68 Million	-131,447 Reduced 10.36%	1,137,092 $21.3 Million
Q1 2021 May 14, 2021	BUY	$20.22 - $26.73 $8.08 Million - $10.7 Million	399,539 Added 45.98%	1,268,539 $30 Million
Q4 2020 Feb 16, 2021	BUY	$23.16 - $28.08 $4.49 Million - $5.45 Million	194,000 Added 28.74%	869,000 $21.2 Million
Q3 2020 Nov 13, 2020	BUY	$24.34 - $38.82 $2.43 Million - $3.88 Million	100,000 Added 17.39%	675,000 $17.3 Million
Q2 2020 Aug 14, 2020	BUY	$19.93 - $31.2 $4.48 Million - $7.02 Million	225,000 Added 64.29%	575,000 $11.5 Million
Q4 2019 Jan 29, 2020	BUY	$19.75 - $33.44 $6.91 Million - $11.7 Million	350,000 New	350,000 $9.2 Million

175

125M

84K

941K

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $491M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Eventide Asset Management, LLC with notifications on news.